A National Registry For Pulmonary Alveolar Proteinosis

Conditions

• Pulmonary Alveolar Proteinosis

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Study Details

The major goal of Part A of this study is to establish a National PAP Registry to help make reliable new research tests available to doctors to improve the diagnosis of PAP, increase awareness and knowledge of PAP, and give patients a 'seat at the table' in planning and conducting PAP research including the clinical testing of several new potential therapies. The major goal of Part B of this study is to define the natural history of autoimmune PAP (aPAP), develop a disease severity score that reflects how aPAP patients feel and function, and to develop and test novel tools to measure the severity of aPAP lung disease. Funding Source - FDA OOPD

Key Dates

First listed

Jun 3, 2015

Start date

Apr 30, 2015

Status verified

Mar 2026

Primary completion

Dec 31, 2030

Completion

Dec 31, 2030

Study Design

Enrollment

500 participants (estimated)

Arms

• Arm: Registry Participants
  All participants who participate in the National PAP Registry will be put into this cohort and observed over approximately 5 years.

Primary Outcome Measure

DBS card GM-CSF autoantibody levels to diagnose Autoimmune PAP [ Time Frame: 5 years ]

Central Contacts

• Brenna C Carey, Ms, PhD
  513-636-8916
  [email protected]

Locations (1)

Find similar trials in Cincinnati, OH